HRP20200325T1 - T-stanični receptori koji prepoznaju mhc razred ii-ograničenog mage-a3 - Google Patents

T-stanični receptori koji prepoznaju mhc razred ii-ograničenog mage-a3 Download PDF

Info

Publication number
HRP20200325T1
HRP20200325T1 HRP20200325TT HRP20200325T HRP20200325T1 HR P20200325 T1 HRP20200325 T1 HR P20200325T1 HR P20200325T T HRP20200325T T HR P20200325TT HR P20200325 T HRP20200325 T HR P20200325T HR P20200325 T1 HRP20200325 T1 HR P20200325T1
Authority
HR
Croatia
Prior art keywords
xaa
seq
gly
ala
ser
Prior art date
Application number
HRP20200325TT
Other languages
English (en)
Croatian (hr)
Inventor
Paul F. Robbins
Steven A. Rosenberg
Xin Yao
Original Assignee
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services, Office Of Technology Transfer, National Institutes Of Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The U.S.A. As Represented By The Secretary, Department Of Health And Human Services, Office Of Technology Transfer, National Institutes Of Health filed Critical The U.S.A. As Represented By The Secretary, Department Of Health And Human Services, Office Of Technology Transfer, National Institutes Of Health
Publication of HRP20200325T1 publication Critical patent/HRP20200325T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
HRP20200325TT 2012-09-14 2013-09-13 T-stanični receptori koji prepoznaju mhc razred ii-ograničenog mage-a3 HRP20200325T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261701056P 2012-09-14 2012-09-14
EP13767200.2A EP2895509B1 (en) 2012-09-14 2013-09-13 T cell receptors recognizing mhc class ii-restricted mage-a3
PCT/US2013/059608 WO2014043441A1 (en) 2012-09-14 2013-09-13 T cell receptors recognizing mhc class ii-restricted mage-a3

Publications (1)

Publication Number Publication Date
HRP20200325T1 true HRP20200325T1 (hr) 2020-06-12

Family

ID=49253425

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20200325TT HRP20200325T1 (hr) 2012-09-14 2013-09-13 T-stanični receptori koji prepoznaju mhc razred ii-ograničenog mage-a3

Country Status (20)

Country Link
US (4) US9879065B2 (OSRAM)
EP (3) EP2895509B1 (OSRAM)
JP (4) JP6461796B2 (OSRAM)
KR (4) KR102303166B1 (OSRAM)
CN (2) CN113754755A (OSRAM)
AU (4) AU2013315391B2 (OSRAM)
CA (1) CA2884743C (OSRAM)
CY (1) CY1122720T1 (OSRAM)
DK (2) DK2895509T3 (OSRAM)
ES (2) ES2774931T3 (OSRAM)
HR (1) HRP20200325T1 (OSRAM)
HU (1) HUE048014T2 (OSRAM)
IL (3) IL286786B (OSRAM)
LT (1) LT2895509T (OSRAM)
MX (2) MX367279B (OSRAM)
PL (1) PL2895509T3 (OSRAM)
PT (1) PT2895509T (OSRAM)
SI (1) SI2895509T1 (OSRAM)
SM (1) SMT202000103T1 (OSRAM)
WO (1) WO2014043441A1 (OSRAM)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102303166B1 (ko) * 2012-09-14 2021-09-17 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Mhc ii형 제한된 mage-a3을 인식하는 t 세포 수용체
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
CN107075479A (zh) 2014-10-02 2017-08-18 美国卫生和人力服务部 分离对癌症特异性突变具有抗原特异性的t细胞的方法
US20170218042A1 (en) * 2014-10-02 2017-08-03 The United State of America, as represented by the Secretary, Department of Health and Human Service Methods of isolating t cell receptors having antigenic specificity for a cancer-specific mutation
PH12021550850A1 (en) * 2015-03-27 2022-10-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various tumors
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
WO2017070042A1 (en) 2015-10-20 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t cell populations using akt inhibitors
WO2017139199A1 (en) 2016-02-10 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible arginase
EP3416668A4 (en) 2016-02-18 2020-02-19 The Wistar Institute Of Anatomy And Biology METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA
GB201604494D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
EP4177264A1 (en) 2016-03-16 2023-05-10 Immatics Biotechnologies GmbH Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
CN106749620B (zh) * 2016-03-29 2020-09-25 广东香雪精准医疗技术有限公司 识别mage-a1抗原短肽的t细胞受体
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
WO2018097951A1 (en) 2016-11-22 2018-05-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mage-a3/a6 antibodies
DE102016123859B3 (de) 2016-12-08 2018-03-01 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
CN108250289B (zh) * 2016-12-28 2021-10-08 香雪生命科学技术（广东）有限公司 源自于mage b6的肿瘤抗原短肽
EP3565535A4 (en) 2017-01-05 2020-12-30 Fred Hutchinson Cancer Research Center SYSTEMS AND METHODS FOR IMPROVING THE EFFECTIVENESS OF A VACCINE
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
US11850262B2 (en) 2017-02-28 2023-12-26 Purdue Research Foundation Compositions and methods for CAR T cell therapy
FI3692140T3 (fi) * 2017-10-05 2023-10-11 Us Health Menetelmiä solujen laajentamiseksi selektiivisesti ekspressoiden TCR:ää vakiolla muriinialueella
US20200316122A1 (en) 2017-10-11 2020-10-08 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods of producing t cell populations using p38 mapk inhibitors
CN109776671B (zh) * 2017-11-14 2022-05-27 杭州康万达医药科技有限公司 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用
CN109837248A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种tcr敲除的靶向mage-a3的t细胞受体基因修饰t细胞及其制备方法和应用
CN109836490A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种靶向mage-a3的t细胞受体、t细胞受体基因修饰t细胞及其制备方法和应用
CN120154716A (zh) 2018-01-22 2025-06-17 恩多塞特公司 Car t细胞的使用方法
JP7774961B2 (ja) 2018-02-06 2025-11-25 シアトル チルドレンズ ホスピタル ディー／ビー／エイ シアトル チルドレンズ リサーチ インスティテュート フルオレセイン結合エーテルリン脂質（ｆｌ－ｐｌｅ）で標識された腫瘍に対して最適なｔ細胞機能を示すフルオレセイン特異的ｃａｒ
CN118374524A (zh) 2018-02-09 2024-07-23 美国卫生和人力服务部 拴系白细胞介素-15和白细胞介素-21
CA3091674A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
JP7469807B2 (ja) 2018-04-19 2024-04-17 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｍａｇｅ－ｂ２特異性を有するｔ細胞受容体およびその使用
CN112262212B (zh) 2018-04-24 2024-07-12 美国卫生和人力服务部 使用羟基柠檬酸和/或其盐产生t细胞群体的方法
EP3714941A1 (en) * 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
CA3146845A1 (en) * 2019-07-15 2021-01-21 Neogene Therapeutics B.V. Method to isolate tcr genes
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
JP2020143057A (ja) * 2020-04-01 2020-09-10 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法
EP4667936A2 (en) 2020-09-08 2025-12-24 The United States of America, as represented by the Secretary, Department of Health and Human Services T cell phenotypes associated with response to adoptive cell therapy
US20240018210A1 (en) 2020-11-13 2024-01-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain
JP2025501259A (ja) 2021-12-31 2025-01-17 アメリカ合衆国 がんに対する組合せ免疫療法としてのワクチン接種を伴うｔ細胞療法
CN117946245B (zh) * 2023-02-23 2024-08-02 暨南大学 一种识别mage-a3抗原短肽的t细胞受体及其应用
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025160480A1 (en) 2024-01-26 2025-07-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Enhanced tumor reactivity of t cells lacking sit1, lax1, or trat1
WO2025250587A1 (en) 2024-05-29 2025-12-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Drug-regulatable, inducible cytokine expression

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IN165717B (OSRAM) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US20020197266A1 (en) 2000-02-08 2002-12-26 Waldemar Debinski Immunotherapy using interleukin 13 receptor subunit alpha 2
WO2012013913A1 (en) * 2010-07-28 2012-02-02 Immunocore Ltd T cell receptors
EP2618835B1 (en) * 2010-09-20 2017-07-05 BioNTech Cell & Gene Therapies GmbH Antigen-specific t cell receptors and t cell epitopes
WO2012054825A1 (en) 2010-10-22 2012-04-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mage-a3 t cell receptors and related materials and methods of use
CN102251033B (zh) * 2011-07-05 2013-03-20 北京大学人民医院 基于mage-a3基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒
SI2755997T1 (sl) 2011-09-15 2018-11-30 The United States of America, as represented by Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni mage
US9413985B2 (en) * 2012-09-12 2016-08-09 Lattice Semiconductor Corporation Combining video and audio streams utilizing pixel repetition bandwidth
KR102303166B1 (ko) * 2012-09-14 2021-09-17 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Mhc ii형 제한된 mage-a3을 인식하는 t 세포 수용체

Also Published As

Publication number Publication date
CA2884743C (en) 2023-03-14
AU2021203746B2 (en) 2024-05-02
US9879065B2 (en) 2018-01-30
AU2019213329A1 (en) 2019-08-29
MX2019009641A (es) 2019-11-28
KR102370307B1 (ko) 2022-03-04
EP4159753A1 (en) 2023-04-05
JP2015535816A (ja) 2015-12-17
AU2017219019A1 (en) 2017-09-14
KR20220031941A (ko) 2022-03-14
ES2774931T3 (es) 2020-07-23
IL286786B (en) 2022-09-01
AU2013315391A1 (en) 2015-04-02
AU2019213329B2 (en) 2021-03-11
IL274003A (en) 2020-05-31
LT2895509T (lt) 2020-03-25
PT2895509T (pt) 2020-03-13
KR102303166B1 (ko) 2021-09-17
SI2895509T1 (sl) 2020-04-30
HUE048014T2 (hu) 2020-05-28
US20200270329A1 (en) 2020-08-27
JP2019088286A (ja) 2019-06-13
US10611815B2 (en) 2020-04-07
US20230089465A1 (en) 2023-03-23
JP7270001B2 (ja) 2023-05-09
MX367279B (es) 2019-08-13
WO2014043441A1 (en) 2014-03-20
MX2015003061A (es) 2015-11-06
IL274003B (en) 2021-10-31
JP2021191265A (ja) 2021-12-16
IL237560A0 (en) 2015-04-30
JP6461796B2 (ja) 2019-01-30
CY1122720T1 (el) 2021-03-12
AU2021203746A1 (en) 2021-07-01
JP6728326B2 (ja) 2020-07-22
SMT202000103T1 (it) 2020-05-08
DK3636665T3 (da) 2022-10-03
JP2020178702A (ja) 2020-11-05
AU2013315391B2 (en) 2017-06-08
PL2895509T3 (pl) 2020-07-27
CN104968675A (zh) 2015-10-07
JP6923714B2 (ja) 2021-08-25
EP2895509B1 (en) 2019-12-04
EP3636665B1 (en) 2022-06-29
AU2017219019B2 (en) 2019-05-09
IL286786A (en) 2021-10-31
CA2884743A1 (en) 2014-03-20
US20150246959A1 (en) 2015-09-03
KR20200118248A (ko) 2020-10-14
EP3636665A1 (en) 2020-04-15
KR102480188B1 (ko) 2022-12-21
CN104968675B (zh) 2021-09-24
KR20150052086A (ko) 2015-05-13
US20180127479A1 (en) 2018-05-10
KR102165350B1 (ko) 2020-10-14
US12404317B2 (en) 2025-09-02
CN113754755A (zh) 2021-12-07
KR20210114563A (ko) 2021-09-23
DK2895509T3 (da) 2020-03-09
EP2895509A1 (en) 2015-07-22
ES2925307T3 (es) 2022-10-14
IL237560B (en) 2020-05-31

Similar Documents

Publication Publication Date Title
HRP20200325T1 (hr) T-stanični receptori koji prepoznaju mhc razred ii-ograničenog mage-a3
JP2015535816A5 (OSRAM)
ES2983771T3 (es) TCR de NY-ESO
JP2025024103A (ja) Ｍａｇｅ ａ４ ｔ細胞受容体
CA3139051A1 (en) Multispecific proteins
ES2545895T3 (es) Proteína de fusión anticancerígena
HRP20221183T1 (hr) T-stanični receptori anti-kras-g12d
EA201291362A1 (ru) Слитый белок против злокачественных новообразований
AR086360A1 (es) Polipeptidos anticuerpos que antagonizan cd40
BR112015009003A2 (pt) receptores de antígeno quiméricos
RU2020113032A (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
MX2022005922A (es) Receptores de tcr de prame y usos de estos.
RU2010122053A (ru) Иммуносупрессорные полипептиды и нуклеиновые кислоты
UA115316C2 (uk) Зв'язувальна молекула, яка зв'язується з cd134 людини, та фармацевтична композиція, що її містить
RU2010147076A (ru) Аналоги инсулина специфичные к изоформам
MX2011009810A (es) Composiciones y metodos para usar proteinas de union multiespecificas que comprenden una combinacion anticuerporeceptor.
CA3025124A1 (en) Herpesvirus with modified glycoprotein h for propagation in a cell
CN113840834B (zh) Magea1特异性t细胞受体及其用途
EP2589658A4 (en) PARTIAL REGION POLYPEPTIDE OF REIC / DKK-3 PROTEIN
RU2015103816A (ru) ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E
EP2970466A1 (en) Targeting vaccines for veterinary use
CN104136609B (zh) 辅助性t细胞诱导多肽的修饰
HRP20240359T1 (hr) Peptidi iz piwil1
US20220340629A1 (en) Myosin Derived Peptides and Related Compounds with Anticoagulant Activities
KR20250021382A (ko) 바이러스 펩티드 및 이의 용도